Randomized, proof-of-concept trial of low dose naltrexone for patients with breakthrough symptoms of major depressive disorder on antidepressants

详细信息    查看全文

• 作者：David Mischoulon ; ^{dmischoulon@partners.org} ; Lindsay Hylek ; Albert S. Yeung ; Alisabet J. Clain ; Lee Baer ; Cristina Cusin ; Dawn Flosnik Ionescu ; Jonathan E. Alpert ; David P. Soskin¹ ; Maurizio Fava¹
• 关键词：Naltrexone ; LDN ; Depression ; Relapse ; Breakthrough
• 刊名：Journal of Affective Disorders
• 出版年：2017
• 出版时间：15 January 2017
• 年：2017
• 卷：208
• 期：Complete
• 页码：6-14
• 全文大小：453 K
• 卷排序：208

文摘

Low-dose naltrexone is thought to function via a dopaminergic mechanism that may have potential antidepressant effects. In 12 depressed subjects who relapsed on pro-dopaminergic antidepressants, low dose naltrexone reduced depression severity. Low-dose naltrexone augmentation may be effective for depressive relapse, but the findings must be interpreted with caution.